跳至主要内容
临床试验/NCT00887601
NCT00887601已完成1 期

A 4-Period, Placebo-Controlled, Crossover Study to Evaluate the Utility and Feasibility of BOLD fMRI and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (Donepezil and MK3134)

Merck Sharp & Dohme LLC0 个研究点目标入组 32 人开始时间: 2007年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
32
主要终点
Part I: Difference in number of voxels activated for both faces and scenes after treatment with donepezil and placebo

研究概览

简要总结

This study will evaluate functional magnetic resonance imaging (fMRI) and methods for measuring drug induced changes in cerebral blood flow as biomarkers for attention-improving drugs.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Diagnostic
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Subject is a nonsmoker
  • Subject is in generally good health
  • Subject has normal (or corrected to normal) vision and hearing
  • Subject is right-handed

排除标准

  • Subject has a history of any illness that would make participation unsafe or would make the study results difficult to interpret
  • Subject has a history of stroke, seizures, or major neurological disorders
  • Subject has a history of cancer
  • Subject has permanent cosmetic or metallic implants that would interfere with measurements
  • Subject has a history of sleep apnea
  • Subject has a history of head injury/trauma

研究组 & 干预措施

Part I

Experimental

Subjects will receive placebo, MK3134, and donepezil in one of four treatment sequences.

干预措施: MK3134 (Drug)

Part I

Experimental

Subjects will receive placebo, MK3134, and donepezil in one of four treatment sequences.

干预措施: Donepezil (Drug)

Part II

Experimental

Subjects will receive placebo and three different doses of MK3134 (1 mg, 5 mg, and 25 mg) in one of four treatment sequences.

干预措施: MK3134 (Drug)

结局指标

主要结局

Part I: Difference in number of voxels activated for both faces and scenes after treatment with donepezil and placebo

时间窗: 3.5 to 4.5 hours after study drug administration

Part II: Number of voxels showing a positive response after varying doses of MK3134 compared to placebo

时间窗: 3.5 to 4.5 hours after study drug administration

Part I: Difference in number of voxels showing a positive response after treatment with donepezil and placebo

时间窗: 3.5 to 4.5 hours after study drug administration

Part II: Number of voxels activated for both faces and scenes after varying doses of MK3134 compared to placebo

时间窗: 3.5 to 4.5 hours after study drug administration

次要结局

  • Part I: Test-retest reproducibility of the BOLD fMRI and cerebral blood flow measurements in donepezil treated subjects(1 to 5 weeks)
  • Part II: Change in arterial transit time after treatment with placebo and varying doses of MK3134(3.5 to 4.5 hours after study drug administration)
  • Part II: Change in Pulsatility index after treatment with placebo and varying doses of MK3134(5 hours after study drug administration)
  • Part I: Difference in Pulsatility index after treatment with donepezil and placebo(5 hours after study drug administration)
  • Part I: Difference in arterial transit time as measured by arterial spin labeling after treatment with donepezil and placebo(3.5 to 4.5 hours after study drug administration)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验

BOLD Functional Magnetic Resonance Imaging (fMRI)... | 临床试验